Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
89Zr-Pembrolizumab Imaging in NSCLC
NCT03065764Phase 2Unknown
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2017
- Primary completion
- Dec 2019
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of pembrolizumab in non-small cell lung cancer (NSCLC), sponsored by Amsterdam University Medical Center. Status: unknown.
02
Drugs
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03065764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03065764.